Print Friendly, PDF & Email

Dr. Bredesen explains the difference between 20th and 21st Century medicine. Previously, patients waited until their symptoms could be easily identified by the doctor who then labeled the disease and treated it with the corresponding drug. Today, in many cases as a result of our western diet and exposure to toxins, chronic illnesses are much more complex. No longer will a monotherapeutic drug be able to treat a multi-factored disease. The shift in medicine today is to find out “why” the patient is ill – discover the underlying causes.

After 30 years of research, Dr. Bredesen discovered Alzheimer’s is a disease with at least 36 contributing factors. The ReCODE ProtocolTM he developed, addresses whatever has contributed to a person’s cognitive decline. The proper testing must be done first to identify the causes and the Alzheimer’s subtype. Then a customized  treatment plan can be prescribed for the patient. The goal is not just to bring levels into the normal range, but to optimize  those levels, giving the patient the best chance of halting and reversing their cognitive decline. Find out more about The Bredesen ProtocolTM here.

Dale E. Bredesen, M.D., UCLA and Buck Institute | Professor of Neurology, Easton Laboratories for Neurodegenerative Disease Research | David Geffen School of Medicine at UCLA, Los Angeles, CA

Founding President and CEO, Professor Emeritus, Buck Institute for Research on Aging, Novato, CA, Dr. Bredesen received his undergraduate degree from Caltech and his medical degree from Duke. He served as Resident and Chief Resident in Neurology at UCSF, then postdoctoral fellow in the laboratory of Nobel laureate Prof. Stanley Prusiner. He was a faculty member at UCLA from 1989-1994, and was then recruited by the Burnham Institute to direct the Program on Aging. In 1998 he became the Founding President and CEO of the Buck Institute for Research on Aging, and Adjunct Professor at UCSF. Then in 2013, he returned to UCLA as the Director of the Easton Center for Alzheimer’s Disease Research.

The Bredesen Laboratory studies basic mechanisms underlying the neurodegenerative process, and the translation of this knowledge into effective therapeutics for Alzheimer’s disease and other neurodegenerative conditions, leading to the publication of over 220 research papers. He established the ADDN (Alzheimer’s Drug Development Network) with Dr. Varghese John in 2008, leading to the identification of new classes of therapeutics for Alzheimer’s disease. Dr. Bredesen’s group has developed a new approach to the treatment of Alzheimer’s disease. This approach has led to the discovery of subtypes of Alzheimer’s disease, followed by the first description of reversal of symptoms in patients with MCI (Mild Cognitive Impairment) and early Alzheimer’s disease, with The ReCODE (reversal of cognitive decline) ProtocolTM, published in 2014 and 2016. His book, The End of Alzheimer’s, is a New York Times Bestseller and is shown below.

Order this book here.
ALZsurvivor [home] > Aspen Brain Lab 2018 – Dr. Dale Bredesen – “The End of Alzheimer’s”: The First Survivors

COVID-19 & ALZ connection (mask)

The TRUTH About Alzheimer’s Drugs . . .

Share It!

See more memes here.
Share 'em - help save lives!

Glossary

ALZ
abbreviation for Alzheimer’s Disease
Alzheimer’s Disease
a type of dementia and a progressive disease of the brain that slowly causes impairment in memory and cognitive function. Alzheimer’s disease happens when the brain tries to protect itself from three metabolic and toxic threats:


1 - Inflammation (from infection, diet or other causes)
2 - Decline and shortage of supportive nutrients, hormones and other brain-supporting molecules
3 - Toxic substances such as metals or biotoxins (poisons produced by microbes such as molds)

The protective response causes APP (Amyloid Precursor Protein, the long molecule that protrudes from neurons) to be cut into four fragments, including amyloid-beta, that downsize the neural network and eventually destroy synapses and neurons. When the APP molecule is cut into those four pieces, it is not cut into the two pieces that nourish and maintain synapses.

Alzheimer's disease is a state of the brain in which there is an imbalance between the reorganization of synapses that have outlived their usefulness (and which the brain can stand to lose - healthy destruction) and the maintenance or creation of existing and new synapses (which the brain needs to sustain old memories and form new ones, as well as perform other cognitive functions). That imbalance  comes from too many  of the synapse- and neuron-destroying quartet  of molecules snipped from APP and too few  of the synapse- and neuron-sustaining duo  of molecules snipped from APP.

ApoE4
abbreviation for apolipoprotein E, a gene variant (allele) which is a protein that carries lipids – i.e. fats. Carrying one ApoE4 (inherited from one parent) increases your lifetime risk of Alzheimer’s to 30 percent. Carrying two copies (from both parents) increases it to 50 to 90 percent. That compares to a risk of only about 9 percent in those who carry zero copies of this allele.
APP
abbreviation for Amyloid Precursor Protein, the long molecule that protrudes from neurons

CognoscopyTM
metabolic and genetic testing that identifies cognitive decline or what may be putting you at risk for it
Dementia
umbrella term for a group of symptoms (a syndrome) without a definitive diagnosis. Dementia is a group of symptoms that affect mental cognitive tasks such as memory and reasoning. (Alzheimer’s Disease is the most common type of dementia.)
Early Alzheimer’s Disease
an early onset of Alzheimer’s Disease and uncommon form of dementia that typically affects those under the age of 65
Functional Medicine
a systems biology–based approach that focuses on identifying and addressing the root cause of disease
Heterozygous
carrying 1 copy of the ApoE4 genetic variant
Homozygous
carrying 2 copies of the ApoE4 genetic variant
Integrative Medicine
healing-oriented medicine that takes account of the whole person, including all aspects of lifestyle. It emphasizes the therapeutic relationship between practitioner and patient, is informed by evidence, and makes use of all appropriate therapies.
Ketoflex 12/3
anti-Alzheimer’s diet to include at least 12 hours of fasting, with the first 3 hours of that fast starting after dinner. It is largely plant based, but flexible as it does allow for small amounts of meat or fish.
MCI
Mild Cognitive Impairment
MCT oil
an abbreviation for medium chain triglyceride (a saturated fat) which is found in coconut oil.  Alzheimer's impairs the brain's ability to use sugar.  An MCT ketogenic diet offers an alternative energy source:  ketones.  This allows brain cells to survive better, blocking a receptor in the brain that causes memory loss.
SCI
Subjective Cognitive Impairment – a precursor to MCI (Mild Cognitive Impairment)
The Bredesen ProtocolTM
treatment program developed by Dr. Dale E. Bredesen to prevent and reverse cognitive decline (also known as The ReCODE ProtocolTM)
The ReCODE ProtocolTM
treatment program developed by Dr. Dale E. Bredesen to prevent and reverse cognitive decline (also known as The Bredesen ProtocolTM)
The ReCODE Report
computer generated report as a result of metabolic and genetic testing (CognoscopyTM)
The ReVERSE Program
customized  treatment program to reverse cognitive decline. This program starts with a ReCODE Report (a computer generated report as a result of metabolic and genetic testing called a CognoscopyTM)

Send this to a friend